EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

The Swiss Primary Hypersomnolence and Narcolepsy Cohort Study: feasibility of long-term monitoring with Fitbit smartwatches in central disorders of hypersomnolence and extraction of digital biomarkers in narcolepsy

Oriella Gnarra iD, Julia van der Meer iD, Jan D Warncke iD, Livia G Fregolente, Elena Wenz iD, Kseniia Zub, Uchendu Nwachukwu, Zhongxing Zhang iD, Ramin Khatami, Sigrid von Manitius, Silvia Miano, Jens Acker und 4 weitere

SLEEP · 2024

DOI: 10.1093/sleep/zsae083 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift SLEEP, 2024. Verfasst von Oriella Gnarra und 15 weiteren Autor:innen. Beteiligte Einrichtung: Sleep-Wake Epilepsy Center, NeuroTec, Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland. Hauptthemen laut MEDLINE: Narcolepsy, Feasibility Studies, Biomarkers, Wearable Electronic Devices. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: Swiss National Science Foundation, UCB Biopharma SRL, Jazz Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Swiss Primary Hypersomnolence and Narcolepsy Cohort Study (SPHYNCS) is a multicenter research initiative to identify new biomarkers in central disorders of hypersomnolence (CDH). Whereas narcolepsy type 1 (NT1) is well characterized, other CDH disorders lack precise biomarkers. In SPHYNCS, we utilized Fitbit smartwatches to monitor physical activity, heart rate, and sleep parameters over 1 year. We examined the feasibility of long-term ambulatory monitoring using the wearable device. We then explored digital biomarkers differentiating patients with NT1 from healthy controls (HC). A total of 115 participants received a Fitbit smartwatch. Using a adherence metric to evaluate the usability of the wearable device, we found an overall adherence rate of 80% over 1 year. We calculated daily physical activity, heart rate, and sleep parameters from 2 weeks of greatest adherence to compare NT1 (n = 20) and HC (n = 9) participants. Compared to controls, NT1 patients demonstrated findings consistent with increased sleep fragmentation, including significantly greater wake-after-sleep onset (p = .007) and awakening index (p = .025), as well as standard deviation of time in bed (p = .044). Moreover, NT1 patients exhibited a significantly shorter REM latency (p = .019), and sleep latency (p = .001), as well as a lower peak heart rate (p = .008), heart rate standard deviation (p = .039) and high-intensity activity (p = .009) compared to HC. This ongoing study demonstrates the feasibility of long-term monitoring with wearable technology in patients with CDH and potentially identifies a digital biomarker profile for NT1. While further validation is needed in larger datasets, these data suggest that long-term wearable technology may play a future role in diagnosing and managing narcolepsy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NarcolepsyFeasibility StudiesBiomarkersWearable Electronic DevicesHumansMaleFemaleAdultSwitzerlandCohort StudiesHeart RateMiddle AgedDisorders of Excessive SomnolenceExercise

Stichwörter der Autor:innen

digital biomarkershypersomnolencenarcolepsytelemonitoringwearables

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Sleep-Wake Epilepsy Center, NeuroTec, Department of Neurology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
  • Sensory-Motor Systems Lab, Department of Health Sciences and Technology, Institute of Robotics and Intelligent Systems, ETH Zurich, Switzerland.
  • Graduate School of Health Sciences, University of Bern, Bern, Switzerland.
  • Clinic Barmelweid, Center for Sleep Medicine and Sleep Research, Barmelweid, Switzerland.
  • Department of Neurology, Kantonsspital St. Gallen, St. Gallen, Switzerland.
  • Neurocenter of Southern Switzerland, Faculty of Biomedical Sciences, Università della Svizzera Italiana, Sleep Medicine Unit, Ospedale Civico, Lugano, Switzerland.

ORCID-Profile: Oriella Gnarra, Julia van der Meer, Jan D Warncke, Elena Wenz, Zhongxing Zhang, Markus H Schmidt

Förderung

  • Swiss National Science Foundation
  • UCB Biopharma SRL
  • Jazz Pharmaceuticals

Zitieren

APA

Gnarra, O., van der Meer, J., Warncke, J. D., Fregolente, L. G., Wenz, E., Zub, K., Nwachukwu, U., Zhang, Z., Khatami, R., von Manitius, S., Miano, S., Acker, J., Strub, M., Riener, R., Bassetti, C. L. A., & Schmidt, M. H. (2024). The Swiss Primary Hypersomnolence and Narcolepsy Cohort Study: feasibility of long-term monitoring with Fitbit smartwatches in central disorders of hypersomnolence and extraction of digital biomarkers in narcolepsy. SLEEP. https://doi.org/10.1093/sleep/zsae083

Vancouver

Gnarra O, van der Meer J, Warncke JD, Fregolente LG, Wenz E, Zub K, et al. The Swiss Primary Hypersomnolence and Narcolepsy Cohort Study: feasibility of long-term monitoring with Fitbit smartwatches in central disorders of hypersomnolence and extraction of digital biomarkers in narcolepsy. SLEEP. 2024. doi:10.1093/sleep/zsae083

BibTeX
@article{Gnarra2024,
  author = {Gnarra, Oriella and van der Meer, Julia and Warncke, Jan D and Fregolente, Livia G and Wenz, Elena and Zub, Kseniia and Nwachukwu, Uchendu and Zhang, Zhongxing and Khatami, Ramin and von Manitius, Sigrid and Miano, Silvia and Acker, Jens and Strub, Mathias and Riener, Robert and Bassetti, Claudio L A and Schmidt, Markus H},
  title = {The Swiss Primary Hypersomnolence and Narcolepsy Cohort Study: feasibility of long-term monitoring with Fitbit smartwatches in central disorders of hypersomnolence and extraction of digital biomarkers in narcolepsy},
  journal = {SLEEP},
  year = {2024},
  doi = {10.1093/sleep/zsae083}
}
Kostenlos starten →